// App-Quantinova.ai

: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.

Researchers

Presenter

  • Thomas Powles

Principal Investigators

  • Viktor Stus

  • Rustem Airatovich Gafanov

  • Robert E. Hawkins

  • Dmitry Nosov

  • Frederic Pouliot

  • Boris Yakovlevich Alekseev

  • Denis Soulieres

  • Bohuslav Melichar

  • Ihor Vynnychenko

  • Anna Kryzhanivska

  • Igor Bondarenko

  • Sergio Jobim Azevedo

  • Delphine Borchiellini

  • Qiong Shou

  • Rodolfo F. Perini

  • Mei Chen

  • Michael B. Atkins

  • Brian I. Rini

Medical Centers

  • Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Fox Chase Cancer Center, Philadelphia, PA

  • Department of Urology State Institution: Dnipropetrovsk Medical Academy under the MHU on the base Dnipropetrovsk I.I. Mechnуkov Regional Clinical Hospital, Dnipropetrovsk, Ukraine

  • Russian Research Centre of Roentgenoradiology, Moscow, Russia

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Central Clinical Hospital, Moscow, Russian Federation

  • CHU de Quebec and Laval University, Quebec, QC, Canada

  • P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russian Federation

  • University of Montreal, Montreal, QC, Canada

  • Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic

  • Sumy State University, Sumy Regional Clinical Oncology Center, Sumy, Ukraine

  • Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine

  • Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine

  • Hospital De Clinicas de Porto Alegre, Porto Alegre RS, Brazil

  • Centre Antoine-Lacassagne, Nice, France

  • MSD China, Beijing, China

  • Merck & Co., Inc., Kenilworth, NJ

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Locations

  • United Kingdom

  • United States

  • Russia

  • Canada

  • Czech Republic

  • Brazil

  • France

  • China

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Sunitinib

  • Inlyta

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Superiority

Phase

  • NA

Study Id's

  • NCT02853331

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved